Stay updated with breaking news from ஹோலி மானிங். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
10 Best Concerts of the Week: Speedealer, Robert Earl Keen, Cure for Paranoia and More dallasobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dallasobserver.com Daily Mail and Mail on Sunday newspapers.
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma – Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in . Agios Pharmaceuticals, Inc.January 17, 2021 GMT CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma. Data from the study were featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held virtually January 15-17, 2021. ....
Published: Dec 21, 2020 CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company. Agios will receive a cash consideration of up to $2.0 billion, including $1.8 billion in upfront cash and $200 million in a potential future milestone payment for vorasidenib, as well as 5% royalties on U.S. net sales of TIBSOVO ....